Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | INFORMATION TO BE INCLUDED IN THE REPORT Item 5.02 Departure of Directors or Certain Officers; Election of Directors; |
| 17.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | RMATION TO BE INCLUDED IN THE REPORT Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appo |
Stammdaten
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Unternehmen & Branche
| Name | CHAMPIONS ONCOLOGY, INC. |
|---|---|
| Ticker | CSBR |
| CIK | 0000771856 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 83,0 Mio. USD |
| Beta | 0,40 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-01-31 | 10-Q | 16,559,000 | -279,000 | -0.02 | 28,447,000 | 4,283,000 |
| 2025-10-31 | 10-Q | 15,035,000 | 268,000 | 0.02 | 30,162,000 | 4,170,000 |
| 2025-07-31 | 10-Q | 13,995,000 | -436,000 | -0.03 | 30,546,000 | 3,508,000 |
| 2025-04-30 | 10-K | 56,944,000 | 4,701,000 | 0.33 | 32,344,000 | 3,772,000 |
| 2025-01-31 | 10-Q | 17,039,000 | 4,495,000 | 0.31 | 30,627,000 | 5,469,000 |
| 2024-10-31 | 10-Q | 13,489,000 | 728,000 | 0.05 | 25,240,000 | 681,000 |
| 2024-07-31 | 10-Q | 14,061,000 | 1,313,000 | 0.09 | 24,933,000 | -332,000 |
| 2024-04-30 | 10-Q | -7,300,000 | 26,132,000 | -1,903,000 | ||
| 2024-04-30 | 10-K | 50,155,000 | -7,276,000 | -0.54 | 26,132,000 | -1,903,000 |
| 2024-01-31 | 10-Q | 12,019,000 | -2,530,000 | -0.19 | 26,787,000 | -2,058,000 |
| 2023-10-31 | 10-Q | 11,573,000 | -2,071,000 | -0.15 | 28,294,000 | 93,000 |
| 2023-07-31 | 10-Q | 12,561,000 | -2,566,000 | -0.19 | 29,906,000 | 1,903,000 |
| 2023-04-30 | 10-K | 53,870,000 | -5,335,000 | -0.39 | 34,311,000 | 4,636,000 |
| 2023-01-31 | 10-Q | 12,773,000 | -2,439,000 | -0.18 | 36,151,000 | 7,064,000 |
| 2022-10-31 | 10-Q | 14,281,000 | -16,000 | 0.00 | 36,364,000 | 9,172,000 |
| 2022-07-31 | 10-Q | 13,745,000 | -319,000 | -0.02 | 34,390,000 | 8,983,000 |
| 2022-04-30 | 10-K | 49,109,000 | 548,000 | 0.04 | 35,378,000 | 9,096,000 |
| 2022-01-31 | 10-Q | 13,193,000 | 787,000 | 0.05 | 33,584,000 | 9,236,000 |
| 2021-10-31 | 10-Q | 11,786,000 | 277,000 | 0.02 | 29,296,000 | 8,071,000 |
| 2021-07-31 | 10-Q | 11,253,000 | -172,000 | -0.01 | 28,108,000 | 7,538,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.